NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 107 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.50 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $94,313 | -98.0% | 23,116 | -93.6% | 0.00% | -100.0% |
| Q3 2022 | $4,747,000 | -72.0% | 362,900 | -72.5% | 0.02% | -73.2% |
| Q2 2022 | $16,931,000 | -65.4% | 1,320,662 | -58.9% | 0.07% | -63.4% |
| Q1 2022 | $48,966,000 | -16.2% | 3,210,871 | -2.6% | 0.19% | -16.7% |
| Q4 2021 | $58,406,000 | +92.6% | 3,297,898 | +128.5% | 0.23% | +75.2% |
| Q3 2021 | $30,332,000 | +78.0% | 1,442,994 | +67.0% | 0.13% | +72.7% |
| Q2 2021 | $17,042,000 | -73.0% | 864,200 | -60.3% | 0.08% | -73.9% |
| Q1 2021 | $63,227,000 | +18.5% | 2,175,000 | +23.5% | 0.30% | +13.5% |
| Q4 2020 | $53,354,000 | +108.0% | 1,761,157 | +9.3% | 0.26% | +98.5% |
| Q3 2020 | $25,645,000 | -14.7% | 1,611,850 | +5.8% | 0.13% | -33.2% |
| Q2 2020 | $30,076,000 | +144.8% | 1,523,585 | +52.9% | 0.20% | +96.0% |
| Q1 2020 | $12,284,000 | – | 996,295 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |